• Gene deletion; HGNC; HGNC:11998; TP53; Zygosity=Heterozygous (PubMed=28636942).
  
• Mutation; HGNC; HGNC:427; ALK; Simple; p.Asp1091Asn (c.3271G>A); ClinVar=VCV000218628; Zygosity=Heterozygous (PubMed=18724359; Cosmic-CLP=949170; DepMap=ACH-001355).
  
• Mutation; HGNC; HGNC:6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Heterozygous (Cosmic-CLP=949170; DepMap=ACH-001355).
  
• Mutation; HGNC; HGNC:11998; TP53; Simple; p.Pro152Leu (c.455C>T); ClinVar=VCV000142766; Zygosity=Heterozygous (Cosmic-CLP=949170; DepMap=ACH-001355).
  

PubMed=8242562; DOI=10.1002/1097-0142(19931201)72:11<3346::AID-CNCR2820721134>3.0.CO;2-E
Wada R.K., Seeger R.C., Brodeur G.M., Einhorn P.A., Rayner S.A., Tomayko M.M., Reynolds C.P.
Human neuroblastoma cell lines that express N-myc without gene amplification.
Cancer 72:3346-3354(1993)

DOI=10.1007/0-306-46872-7_2
Thiele C.J.
Neuroblastoma.
(In book chapter) Human cell culture. Vol. 1. Cancer cell lines part 1; Masters J.R.W., Palsson B.O. (eds.); pp.21-53; Kluwer Academic Publishers; New York; USA (1999)

PubMed=11507071
Keshelava N., Zuo J.J., Chen P., Waidyaratne S.N., Luna M.C., Gomer C.J., Triche T.J., Reynolds C.P.
Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines.
Cancer Res. 61:6185-6193(2001)

PubMed=15150091; DOI=10.1158/0008-5472.CAN-03-0809
Schaefer K.-L., Brachwitz K., Wai D.H., Braun Y., Diallo R., Korsching E., Eisenacher M., Voss R., van Valen F., Baer C., Selle B., Spahn L., Liao S.-K., Lee K.A.W., Hogendoorn P.C.W., Reifenberger G., Gabbert H.E., Poremba C.
Expression profiling of t(12;22) positive clear cell sarcoma of soft tissue cell lines reveals characteristic up-regulation of potential new marker genes including ERBB3.
Cancer Res. 64:3395-3405(2004)

PubMed=15720811; DOI=10.1593/neo.04310; PMCID=PMC1531688
Walton J.D., Kattan D.R., Thomas S.K., Spengler B.A., Guo H.-F., Biedler J.L., Cheung N.-K.V., Ross R.A.
Characteristics of stem cells from human neuroblastoma cell lines and in tumors.
Neoplasia 6:838-845(2004)

PubMed=15892104; DOI=10.1002/gcc.20198
Mosse Y.P., Greshock J., Margolin A.A., Naylor T., Cole K.A., Khazi D., Hii G., Winter C., Shahzad S., Asziz M.U., Biegel J.A., Weber B.L., Maris J.M.
High-resolution detection and mapping of genomic DNA alterations in neuroblastoma.
Genes Chromosomes Cancer 43:390-403(2005)

PubMed=16822308; DOI=10.1186/1471-2407-6-177; PMCID=PMC1533846
Dam V., Morgan B.T., Mazanek P., Hogarty M.D.
Mutations in PIK3CA are infrequent in neuroblastoma.
BMC Cancer 6:177.1-177.10(2006)

PubMed=18724359; DOI=10.1038/nature07261; PMCID=PMC2672043
Mosse Y.P., Laudenslager M., Longo L., Cole K.A., Wood A., Attiyeh E.F., Laquaglia M.J., Sennett R., Lynch J.E., Perri P., Laureys G., Speleman F., Kim C., Hou C.-P., Hakonarson H., Torkamani A., Schork N.J., Brodeur G.M., Tonini G.P., Rappaport E., Devoto M., Maris J.M.
Identification of ALK as a major familial neuroblastoma predisposition gene.
Nature 455:930-935(2008)

PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113
Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=23202128; DOI=10.1038/ng.2493; PMCID=PMC3557959
Sausen M., Leary R.J., Jones S., Wu J., Reynolds C.P., Liu X.-Y., Blackford A.L., Parmigiani G., Diaz L.A. Jr., Papadopoulos N., Vogelstein B., Kinzler K.W., Velculescu V.E., Hogarty M.D.
Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma.
Nat. Genet. 45:12-17(2013)

PubMed=24792489; DOI=10.1007/s11060-014-1456-8
Farooqi A.S., Dagg R.A., Choi L.M.R., Shay J.W., Reynolds C.P., Lau L.M.S.
Alternative lengthening of telomeres in neuroblastoma cell lines is associated with a lack of MYCN genomic amplification and with p53 pathway aberrations.
J. Neurooncol. 119:17-26(2014)

PubMed=25884760; DOI=10.1371/journal.pcbi.1004130; PMCID=PMC4401789
Palacios-Moreno J., Foltz L., Guo A.-L., Stokes M.P., Kuehn E.D., George L., Comb M.J., Grimes M.L.
Neuroblastoma tyrosine kinase signaling networks involve FYN and LYN in endosomes and lipid rafts.
PLoS Comput. Biol. 11:e1004130.1-e1004130.33(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=28350380; DOI=10.1038/sdata.2017.33; PMCID=PMC5369315
Harenza J.L., Diamond M.A., Adams R.N., Song M.M., Davidson H.L., Hart L.S., Dent M.H., Fortina P., Reynolds C.P., Maris J.M.
Transcriptomic profiling of 39 commonly-used neuroblastoma cell lines.
Sci. Data 4:170033-170033(2017)

PubMed=28636942; DOI=10.1016/j.celrep.2017.05.087
Dagg R.A., Pickett H.A., Neumann A.A., Napier C.E., Henson J.D., Teber E.T., Arthur J.W., Reynolds C.P., Murray J., Haber M., Sobinoff A.P., Lau L.M.S., Reddel R.R.
Extensive proliferation of human cancer cells with ever-shorter telomeres.
Cell Rep. 19:2544-2556(2017)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=31631027; DOI=10.1016/j.ccell.2019.09.002; PMCID=PMC6851493
Qadeer Z.A., Valle-Garcia D., Hasson D., Sun Z., Cook A., Nguyen C., Soriano A., Ma A.-Q., Griffiths L.M., Zeineldin M., Filipescu D., Jubierre L., Chowdhury A., Deevy O., Chen X., Finkelstein D.B., Bahrami A., Stewart E., Federico S.M., Gallego S., Dekio F., Fowkes M.E., Meni D., Maris J.M., Weiss W.A., Roberts S.S., Cheung N.-K.V., Jin J., Segura M.F., Dyer M.A., Bernstein E.
ATRX in-frame fusion neuroblastoma is sensitive to EZH2 inhibition via modulation of neuronal gene signatures.
Cancer Cell 36:512-527.e9(2019)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010; PMCID=PMC9387775
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)